A pathology-based surrogate model for chemotherapy decision-making in intermediate-risk luminal breast cancer: validation of histologic grade and Ki67 in a Chinese population
Our findings validate the histological grade and a Ki67 index ≥ 20% as predictive biomarkers of chemotherapy responsiveness in intermediate-risk luminal-subtype breast cancer. This evidence-based stratification offers clinical guidance for resource-constrained settings, while further prospective validation and integration with emerging biomarkers are warranted to refine precision therapeutic strategies.
Authors
- Yuan Zeng (ORCID: https://orcid.org/0000-0003-1379-7840)
- Yu Sun (ORCID: https://orcid.org/0000-0003-3938-7057)
- Guanhong Li
Institutions
- Affiliated Hospital of Guizhou Medical University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-02-05
- DOI
- https://doi.org/10.3389/fmed.2026.1727768
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00